Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects
who require large reductions in cholesterol. The study evaluates if selecting the starting
dose based on baseline and target LDL-C cholesterol would provide better results (ie
proportion of subjects resching target)
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.